SCHEDULE: Millennium Entities Disclose Significant Passive Stake in NeoGenomics

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, reporting a collective passive beneficial ownership of up to 2.8% of NeoGenomics, Inc.'s common stock as of June 30, 2025.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed an amended Schedule 13G concerning their beneficial ownership in NeoGenomics, Inc.
• As of June 30, 2025, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 3,566,808 shares of NeoGenomics, Inc. common stock, representing 2.8% of the class.
• Integrated Core Strategies (US) LLC beneficially owns 2,868,103 shares, representing 2.2% of the class.
• The reporting persons hold these shares with shared voting and shared dispositive power.
• The acquisition of these securities was for investment purposes and not with the intent to change or influence the control of NeoGenomics, Inc., consistent with a passive investment strategy.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) reporting passive beneficial ownership. It does not contain subjective language or performance data that would indicate a positive or negative sentiment regarding the issuer's operations or financial health.

Positives

• The filing indicates a significant passive investment by Millennium Management LLC and its affiliates, a prominent investment firm, which could be viewed as a vote of confidence in NeoGenomics, Inc.

Negatives

• No specific negative information regarding NeoGenomics, Inc. is disclosed in this ownership filing.

Risks

• No specific operational or financial risks for NeoGenomics, Inc. are detailed in this ownership disclosure.

Future Outlook

NA

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a significant investment by a major hedge fund in a company operating in the healthcare diagnostics sector, specifically NeoGenomics, Inc., which focuses on cancer testing and information services. Such investments by large institutional players can signal perceived value or strategic interest within the specialized diagnostics market.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for passive investors acquiring more than 5% of a company's stock.
• The percentages reported (up to 2.8% for individual entities within the group, but collectively over 5% for the group, triggering the filing) are typical for institutional passive stakes.
• No specific comparable companies, projects, or results are mentioned in the document to assess performance against industry benchmarks.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a prominent investment firm like Millennium Management LLC could be viewed positively by existing shareholders, potentially signaling institutional confidence or attracting further investor interest.

Key Dates

Keywords

NeoGenomics, Millennium Management, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, healthcare, diagnostics